Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.36 |
| ▸ | KDM5A | P29375 | 3/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22416464 | 0.91 | DNM1 (0.42) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL10760736 | 0.91 | DNM1 (0.52) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL27445854 | 0.91 | DNM1 (0.52) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL27445816 | 0.91 | DNM1 (0.52) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL19040866 | 0.88 | DNM1 (0.50) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL21440037 | 0.88 | DNM1 (0.55) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL27277174 | 0.86 | DNM1 (0.48) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL25963855 | 0.86 | DNM1 (0.52) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL10380694 | 0.85 | DNM1 (0.57) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL27445832 | 0.85 | DNM1 (0.57) | DNM1S1PR2S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | MTREX, HAVCR2, TSG101 | DNM1 1194/4885S1PR2 1949/4885S1PR1 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.